← Back to guidelines
Transplantation3 papers

Mycotic corneal ulcer of left eye

Last edited:

Overview

Mycotic corneal ulcers, also known as fungal keratitis, represent a serious ocular infection that can lead to significant visual impairment or loss, particularly in immunocompromised individuals and those with prior ocular surgeries such as penetrating keratoplasty (PK) or lamellar keratoplasty (LK). The pathophysiology and management of these ulcers can vary based on the type of corneal transplant performed, with LK potentially offering distinct advantages due to differences in immune exposure compared to PK. This guideline aims to provide a comprehensive overview of the clinical considerations, diagnostic approaches, and management strategies for mycotic corneal ulcers in the context of LK of the left eye, with a focus on special populations who may be at higher risk.

Pathophysiology

Mycotic corneal ulcers arise from the invasion of fungal pathogens into the corneal tissue, often following trauma or surgery. The pathophysiology of these ulcers can be influenced significantly by the type of corneal graft performed. In the context of LK, where the donor tissue does not directly contact the aqueous humor, the immune response dynamics differ from those seen in PK, where the donor cornea is in direct contact with the aqueous humor [PMID:19657979]. This separation in LK may reduce the intensity of immune reactions against the graft, potentially altering the susceptibility to secondary infections like fungal ulcers. Understanding these immune modulation effects is crucial for managing complications in transplant patients, as it suggests that LK might offer a more stable environment for graft survival, thereby possibly reducing the risk of opportunistic infections compared to PK. Clinically, this implies that while both types of grafts require vigilant monitoring, LK recipients might benefit from tailored prophylactic strategies to further mitigate infection risks.

Diagnosis

Diagnosing mycotic corneal ulcers involves a combination of clinical examination and laboratory testing. Key clinical signs include stromal infiltration, feathery margins, satellite lesions, and a history of ocular trauma or surgery. In transplant patients, particularly those with LK, clinicians should maintain a high index of suspicion for fungal etiology, especially if there is a history of immunosuppression or delayed healing [PMID:19657979]. Diagnostic confirmation typically relies on corneal scraping and culture, which can identify the specific fungal species responsible for the infection. Additionally, confocal microscopy and confocal laser scanning microscopy can provide rapid, high-resolution images of the corneal layers, aiding in early detection and monitoring of ulcer progression. Given the potential for lower immune exposure in LK, clinicians should be particularly attentive to subtle signs of infection that might otherwise be masked by reduced immune reactivity.

Management

The management of mycotic corneal ulcers in LK recipients involves a multifaceted approach aimed at eradicating the infection while preserving graft integrity. Early and accurate diagnosis is paramount, as delays can lead to deeper stromal involvement and increased complexity in treatment [PMID:19657979]. Antifungal therapy is the cornerstone of treatment, with topical agents such as natamycin, voriconazole, and amphotericin B being commonly prescribed based on the identified fungal species. The reduced immune exposure in LK might necessitate a more cautious approach to ensure that the immune system does not overreact to the antifungal agents, potentially complicating graft survival. Therefore, close monitoring of both the ulcer and graft status is essential. In cases where topical therapy fails, systemic antifungal therapy may be considered, especially in immunocompromised patients. Surgical interventions, including therapeutic keratoplasty or debridement, might be required for severe or refractory cases, although these should be approached with caution to avoid further compromising the graft.

Antifungal Therapy

  • Topical Agents: Initiate with broad-spectrum antifungals like natamycin 5% or voriconazole 1%, applied frequently (every 1-2 hours initially) until clinical improvement is observed.
  • Systemic Therapy: Consider systemic antifungals such as itraconazole or amphotericin B if there is no response to topical therapy or in cases of deep stromal involvement.
  • Monitoring and Follow-Up

  • Regular Examinations: Schedule frequent slit-lamp examinations to monitor ulcer healing and graft stability.
  • Corneal Cultures: Repeat corneal scrapings and cultures to ensure eradication of the fungus and to guide therapy adjustments if necessary.
  • Special Populations

    Patients who have undergone LK for corneal transplantation, especially those with underlying immunosuppression, represent a special population with unique considerations for managing mycotic corneal ulcers. The reduced immune exposure in LK, as highlighted by studies demonstrating lower rejection rates compared to PK [PMID:19657979], suggests that these patients might have a more stable graft environment, potentially reducing the risk of immune-mediated complications. However, this does not negate the need for vigilant monitoring and proactive management of infectious risks. Immunocompromised individuals are particularly vulnerable to opportunistic fungal infections, necessitating heightened surveillance and possibly more aggressive prophylactic measures. Clinicians should consider tailored prophylactic antifungal strategies, especially in patients with a history of recurrent infections or those on immunosuppressive medications. Additionally, optimizing overall systemic health and minimizing additional stressors (e.g., trauma, environmental exposures) can further support graft survival and reduce the incidence of secondary complications like mycotic ulcers.

    Key Recommendations

  • Early Diagnosis: Maintain a high index of suspicion for fungal keratitis in LK recipients, especially those with immunosuppression or delayed healing.
  • Comprehensive Diagnostic Workup: Utilize corneal scrapings, cultures, and advanced imaging techniques like confocal microscopy for accurate diagnosis.
  • Tailored Antifungal Therapy: Initiate appropriate topical antifungal therapy based on identified pathogens and consider systemic therapy if necessary.
  • Close Monitoring: Regular follow-up examinations and repeated cultures to ensure effective treatment and graft stability.
  • Prophylactic Measures: Implement prophylactic strategies in high-risk patients to minimize infection risks, considering individual immune status and clinical history.
  • By adhering to these recommendations, clinicians can better manage mycotic corneal ulcers in LK recipients, safeguarding both visual outcomes and graft survival.

    References

    1 Huang T, Planck SR, Rosenbaum JT, Lee EJ. Feasibility study of lamellar keratoplasty in a murine model. Ocular immunology and inflammation 2009. link

    1 papers cited of 3 indexed.

    Original source

    1. [1]
      Feasibility study of lamellar keratoplasty in a murine model.Huang T, Planck SR, Rosenbaum JT, Lee EJ Ocular immunology and inflammation (2009)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG